Jobs
-
AstraZeneca has announced today that it will acquire 100% of the shares of inhaled drug developer Pearl Therapeutics for $560 million, plus up to $450 million in milestone payments and an additional $140 million if… Read more . . .
-
Hovione has announced the appointment of Justin Hughey, who was most recently Director of Research for Enavail to head its US Particle Design sciences at our site in New Jersey. The company says that it… Read more . . .
-
Finnish drug developer Biotie Therapies has announced that it is paying $1 million for an exclusive option to acquire Neurelis, Inc., which is developing NRL-1, an intranasal diazepam formulation for the treatment of epilepsy. The… Read more . . .
-
Jolyon Mitchell has long been a leading voice in OINDP development and analysis through numerous publications and through service to multiple organizations . . . Read more Read more . . .
-
Device manufacturer Rexam Healthcare has announced a €20 million expansion of its manufacturing operations at its site in Le Tréport, France, giving the site a total workspace of 5200 sq m. Rexam will manufacture the… Read more . . .
-
Israeli device company Inspiro Medical has announced that a safety and efficacy study of formoterol delivered by the Inspiromatic dry powder inhaler for the treatment of asthma in children met both its primary and secondary… Read more . . .
-
Meda has announced an expansion in its partnership with Cipla, which is already supplying azelastine for Meda’s Dymista nasal spray. With the new agreement, Meda will continue to take responsibility for clinical development and commercialization… Read more . . .
-
According to Genoa Pharmaceuticals, a pre-clinical study conducted at McMaster University demonstrated that the company’s GP-101 inhaled pirfenidone demonstrated statistically significant greater anti-fibrotic effect in an in vivo model of pulmonary fibrosisi than did higher… Read more . . .
-
Irish biotech company Elan, which recently paid $1 billion to Theravance for royalty payments from sales of Breo (Relvar) Ellipta and other inhaled drugs, has been awarded an injunction against Royalty Pharma by an Irish… Read more . . .
-
Submit abstracts for posters and podium presentations by July 26, 2013 at http://www.ddl-conference.org.uk/?q=abstractsubmissionDDL24 Full guidelines available at http://www.ddl-conference.org.uk/files2/Abstract_Guidelines_2013.pdf. Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK